Reference(s)
Click here to return to the Reference Table

Cancer type: Kidney


HGF/SF expression

Reference Number: 60
Oh, R. R. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Apmis 110, 229-38 (2002).
PubMed link      E-mail link

Reference Number: 286
Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171, 2166-70 (2004)
PubMed link      E-mail link

Reference Number: 490
Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A. 103, 14531-6 (2006)
PubMed link      E-mail link

Reference Number: 529
Peruzzi B, Bottaro DP. Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle. 5, 2839-41 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 670
Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55, 106-11 (2008)
PubMed link      E-mail link

Reference Number: 732
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin Cancer Res. 15, 2723-30 (2009)
PubMed link      E-mail link

Reference Number: 833
Xie LQ, Bian LJ, Li Z, Li Y, Liang YJ. Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma. Oncol Rep. 23, 141-50 (2010)
PubMed link      E-mail link

Reference Number: 1120
Vidyashankar S, Varma SR, Azeemudin M, Godavarthi A, Krishna NS, Patki PS. A novel herbal formulation "LiverCare" differentially regulates primary rat hepatocyte and hepatocarcinoma cell proliferation in vitro. J Med Food. 14, 1023-31 (2011)
PubMed link      E-mail link

Reference Number: 1600
Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 289, 20448-61 (2014)
PubMed link      E-mail link

Reference Number: 1623
Du T, Ju G, Wu S, Cheng Z, Cheng J, Zou X, Zhang G, Miao S, Liu G, Zhu Y. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One. 9, e96836 (2014)
PubMed link      E-mail link

Met expression

Reference Number: 60
Oh, R. R. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Apmis 110, 229-38 (2002).
PubMed link      E-mail link

Reference Number: 61
Inoue, K. et al. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth. Virchows Arch 433, 511-5 (1998).
PubMed link      E-mail link

Reference Number: 62
Nakopoulou, L. et al. Immunodetection of c-met-oncogene's protein product in renal cell neoplasia. Pathol Res Pract 193, 299-304 (1997).
PubMed link      E-mail link

Reference Number: 258
Sweeney P, El-Naggar AK, Lin SH, Pisters LL. Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 168:51-5 (2002).
PubMed link      E-mail link

Reference Number: 286
Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171, 2166-70 (2004)
PubMed link      E-mail link

Reference Number: 492
Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res. 12, 4876-81 (2006)
PubMed link      E-mail link

Reference Number: 493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci. 21, 672-7 (2006)
PubMed link      E-mail link

Reference Number: 495
Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 66, 3699-705 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 33, 271-6 (2008)
PubMed link      E-mail link

Reference Number: 732
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic GM, Jones C. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development. Clin Cancer Res. 15, 2723-30 (2009)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 998
Nagi FM, Omar AA, Mostafa MG, Mohammed EA, Abd-Elwahed Hussein MR. The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt. Ultrastruct Pathol. 35, 79-86 (2011)
PubMed link      E-mail link

Reference Number: 1003
Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A. 108, 1439-44 (2011)
PubMed link      E-mail link

Reference Number: 1022
Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG Jr, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 19, 5902-12 (1999)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Reference Number: 1374
Xia QY, Rao Q, Shen Q, Shi SS, Li L, Liu B, Zhang J, Wang YF, Shi QL, Wang JD, Ma HH, Lu ZF, Yu B, Zhang RS, Zhou XJ. Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features. Int J Clin Exp Pathol. 6, 1392-9 (2013)
PubMed link      E-mail link

Reference Number: 1379
Ramakrishnan S1, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5, 453-62 (2013)
PubMed link      E-mail link

Reference Number: 1549
Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, Liu D, Huang Y. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol. 35, 5833-43 (2014)
PubMed link      E-mail link

Reference Number: 1699
Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 290, 8110-20 (2015)
PubMed link      E-mail link

Reference Number: 1754
Mukai S, Yorita K, Kawagoe Y, Katayama Y, Nakahara K, Kamibeppu T, Sugie S, Tukino H, Kamoto T, Kataoka H Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.Hum Cell. 28, 44-50 (2015)
PubMed link      E-mail link

Reference Number: 1865
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther. 16, 743-9 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 493
Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH. MET expression in sporadic renal cell carcinomas. J Korean Med Sci. 21, 672-7 (2006)
PubMed link      E-mail link

Reference Number: 539
Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 98, 491-8 (2007)
PubMed link      E-mail link

Reference Number: 670
Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, Nakanishi R, Yamamoto Y, Taue R, Yamaguchi K, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Takahashi M, Kanayama HO. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. J Med Invest. 55, 106-11 (2008)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Mutation of Met

Reference Number: 64
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A 95, 14417-22 (1998).
PubMed link      E-mail link

Reference Number: 65
Lorenzato, A. et al. d invasion. Cancer Res 62, 7025-30 (2002).
PubMed link      E-mail link

Reference Number: 66
Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer 82, 640-3 (1999).
PubMed link      E-mail link

Reference Number: 67
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16, 68-73 (1997).
PubMed link      E-mail link

Reference Number: 68
Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58, 1719-22 (1998).
PubMed link      E-mail link

Reference Number: 69
Schmidt, L. et al. . Oncogene 18, 2343-50. (1999).
PubMed link      E-mail link

Reference Number: 276
Michieli P, Basilico C, Pennacchietti S, Maffe A, Tamagnone L, Giordano S, Bardelli A, Comoglio PM. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18:5221-31 (1999).
PubMed link      E-mail link

Reference Number: 277
Maritano D, Accornero P, Bonifaci N, Ponzetto C. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene 19:1354-61 (2000).
PubMed link      E-mail link

Reference Number: 278
Chiara F, Michieli P, Pugliese L, Comoglio PM. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity. J Biol Chem. 278, 29352-8 (2003)
PubMed link      E-mail link

Reference Number: 279

Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, Zbar B. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins. 44, 32-43 (2001)

PubMed link      E-mail link

Reference Number: 280
Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, Warren MB, Choyke PL, Torres-Cabala CA, Merino MJ, Brunet J, Berez V, Borras J, Sesia G, Middelton L, Phillips JL, Stolle C, Zbar B, Pautler SE, Linehan WM. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 172, 1256-61 (2004)
PubMed link      E-mail link

Reference Number: 330
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101, 17198-203 (2004)


PubMed link      E-mail link

Reference Number: 335
Prat E, Bernués M, Del Rey J, Camps J, Ponsa I, Algaba F, Egozcue J, Caballín MR, Gelabert A, Miró R. Common pattern of unusual chromosome abnormalities in hereditary papillary renal carcinoma. Cancer Genet Cytogenet. 164, 142-7 (2006)
PubMed link      E-mail link

Reference Number: 340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-93 (2004)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 638
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 33, 271-6 (2008)
PubMed link      E-mail link

Reference Number: 686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4

PubMed link      E-mail link

Reference Number: 726
Resorlu B, Baltaci S, Resorlu M, Kankaya D, Savas B. Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. Turk J Gastroenterol. 18, 47-9 (2007)
PubMed link      E-mail link

Reference Number: 929
Lim JC, Wojcik EM. Fine-needle aspiration cytology of papillary renal cell carcinoma: the association with concomitant secondary malignancies. Diagn Cytopathol. 34, 797-800 (2006)
PubMed link      E-mail link

Reference Number: 981
Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 94, 11445-50 (1997)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1023
Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test. 5, 101-6 (2001)
PubMed link      E-mail link

Reference Number: 1262
Wadt KA, Gerdes AM, Hansen TV, Toft BG, Friis-Hansen L, Andersen MK. Novel germline c-MET mutation in a family with hereditary papillary renal carcinoma. Fam Cancer. 11, 535-7 (2012)
PubMed link      E-mail link

Reference Number: 1378
Harshman LC1, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 19, 316-23 (2013)
PubMed link      E-mail link

Reference Number: 1547
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 21, 81-90 (2014)
PubMed link      E-mail link

Reference Number: 1604
Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couvé S, Gad S, Patard JJ, Escudier B. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 20, 3411-21 (2014)
PubMed link      E-mail link

Reference Number: 1643
Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 47, 13-21 (2015)
PubMed link      E-mail link

Reference Number: 1868
Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, Rodriguez-Antona C. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol Oncol. 33, 179-86 (2015)
PubMed link      E-mail link

In vitro studies

Reference Number: 220
Miyata, Y. et al. Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. Biochem Biophys Res Commun 302:892-7 (2003). 
PubMed link      E-mail link

Reference Number: 282
Heiz M, Grunberg J, Schubiger PA, Novak-Hofer I. Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1: role of the L1 cytoplasmic domain. J. Biol Chem 279, 31149-56 (2004)
PubMed link      E-mail link

Reference Number: 285
Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 171, 890-6 (2004)
PubMed link      E-mail link

Reference Number: 490
Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A. 103, 14531-6 (2006)
PubMed link      E-mail link

Reference Number: 495
Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 66, 3699-705 (2006)
PubMed link      E-mail link

Reference Number: 529
Peruzzi B, Bottaro DP. Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease. Cell Cycle. 5, 2839-41 (2006)
PubMed link      E-mail link

Reference Number: 696
Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol. 181, 6384-93 (2008)
PubMed link      E-mail link

Reference Number: 961
Copeland E, Balgobin S, Lee CM, Rozakis-Adcock M. hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas. Oncogene. 30, 2252-63 (2011)
PubMed link      E-mail link

Reference Number: 1120
Vidyashankar S, Varma SR, Azeemudin M, Godavarthi A, Krishna NS, Patki PS. A novel herbal formulation "LiverCare" differentially regulates primary rat hepatocyte and hepatocarcinoma cell proliferation in vitro. J Med Food. 14, 1023-31 (2011)
PubMed link      E-mail link

Reference Number: 1646
Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, Axelson H, Miao YR, Krieg AJ, Giaccia AJ. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 111, 13373-8 (2014)
PubMed link      E-mail link

Animal models

Reference Number: 220
Miyata, Y. et al. Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo. Biochem Biophys Res Commun 302:892-7 (2003). 
PubMed link      E-mail link

Reference Number: 256
Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res 63:4952-9 (2003).
PubMed link      E-mail link

Reference Number: 330
Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 101, 17198-203 (2004)


PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 986
Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF. Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One. 5, e13586 (2010)
PubMed link      E-mail link

Reference Number: 1623
Du T, Ju G, Wu S, Cheng Z, Cheng J, Zou X, Zhang G, Miao S, Liu G, Zhu Y. Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor. PLoS One. 9, e96836 (2014)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-93 (2004)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4

PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1108
Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 108, 679-86 (2011)
PubMed link      E-mail link

Reference Number: 1274
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 118, 5894-902 (2012)
PubMed link      E-mail link

Reference Number: 1311
Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol. 190, 285-90 (2013)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Reference Number: 1549
Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, Liu D, Huang Y. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol. 35, 5833-43 (2014)
PubMed link      E-mail link

Reference Number: 1729
Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 14, 101-10 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 737
Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 7, 277-85 (2010)
PubMed link      E-mail link

Reference Number: 742
Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 61, 329-43 (2010)
PubMed link      E-mail link

Reference Number: 752
Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 9, 785-93 (2009)
PubMed link      E-mail link

Reference Number: 783
Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 4, 855-68 (2004)
PubMed link      E-mail link

Reference Number: 788
Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 170(6 Pt 1), 2163-72 (2003)
PubMed link      E-mail link

Reference Number: 885
Sánchez P, Calvo E, Durán I. Non-clear cell advanced kidney cancer: is there a gold standard? Anticancer Drugs. 22, Suppl 1:S9-14 (2011)
PubMed link      E-mail link

Reference Number: 886
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 10, 658-64 (2010)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1346
Logan TF. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer. Curr Oncol Rep. 15, 83-90 (2013)
PubMed link      E-mail link

Reference Number: 1547
Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis. 21, 81-90 (2014)
PubMed link      E-mail link

Reference Number: 1605
Fay AP, Signoretti S, Choueiri TK. MET as a target in papillary renal cell carcinoma. Clin Cancer Res. 20, 3361-3 (2014)
PubMed link      E-mail link